Comparative Pharmacology
Head-to-head clinical analysis: ENDEP versus PRAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDEP versus PRAMINE.
ENDEP vs PRAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake in the central nervous system.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentration in the synaptic cleft.
Initial 75 mg/day orally in divided doses, increased gradually to 150-200 mg/day; maintenance 50-150 mg/day as single dose at bedtime or in divided doses.
Imipramine (PRAMINE) 75-150 mg orally once daily at bedtime, titrated from 25-50 mg, max 300 mg/day.
None Documented
None Documented
Terminal elimination half-life: 15-40 hours (mean ~24 h); clinical context: steady-state achieved in 5-7 days; prolonged in elderly and CYP2D6 poor metabolizers.
Clinical Note
moderateImipramine + Torasemide
"The risk or severity of adverse effects can be increased when Imipramine is combined with Torasemide."
Clinical Note
moderateClomipramine + Torasemide
"The risk or severity of adverse effects can be increased when Clomipramine is combined with Torasemide."
Clinical Note
moderateImipramine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Imipramine is combined with Etacrynic acid."
Clinical Note
moderateClomipramine + Etacrynic acid
10-12 hours (terminal elimination half-life; may be prolonged in elderly and hepatic impairment)
Renal: 70-80% as metabolites (including glucuronides, unchanged drug <5%); Biliary/Fecal: 20-30%.
Renal: 70% (as metabolites); Fecal: 30% (as metabolites and unchanged drug)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant
"The risk or severity of adverse effects can be increased when Clomipramine is combined with Etacrynic acid."